326 related articles for article (PubMed ID: 27154248)
1. IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in vivo.
Saeed J; Kitaura H; Kimura K; Ishida M; Sugisawa H; Ochi Y; Kishikawa A; Takano-Yamamoto T
Immunol Lett; 2016 Jul; 175():8-15. PubMed ID: 27154248
[TBL] [Abstract][Full Text] [Related]
2. Muramyl dipeptide enhances lipopolysaccharide-induced osteoclast formation and bone resorption through increased RANKL expression in stromal cells.
Ishida M; Kitaura H; Kimura K; Sugisawa H; Aonuma T; Takada H; Takano-Yamamoto T
J Immunol Res; 2015; 2015():132765. PubMed ID: 26000311
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors.
Strålberg F; Kassem A; Kasprzykowski F; Abrahamson M; Grubb A; Lindholm C; Lerner UH
J Leukoc Biol; 2017 May; 101(5):1233-1243. PubMed ID: 28196851
[TBL] [Abstract][Full Text] [Related]
4. The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-
Shen WR; Kimura K; Ishida M; Sugisawa H; Kishikawa A; Shima K; Ogawa S; Qi J; Kitaura H
J Immunol Res; 2018; 2018():5783639. PubMed ID: 29725604
[TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide of Aggregatibacter actinomycetemcomitans up-regulates inflammatory cytokines, prostaglandin E2 synthesis and osteoclast formation in interleukin-1 receptor antagonist-deficient mice.
Mizutani H; Ishihara Y; Izawa A; Fujihara Y; Kobayashi S; Gotou H; Okabe E; Takeda H; Ozawa Y; Kamiya Y; Kamei H; Kikuchi T; Yamamoto G; Mitani A; Nishihara T; Noguchi T
J Periodontal Res; 2013 Dec; 48(6):748-56. PubMed ID: 23586622
[TBL] [Abstract][Full Text] [Related]
6. IL-4 inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL expression in TNF-α-activated stromal cells and direct inhibition of TNF-α-activated osteoclast precursors via a T-cell-independent mechanism in vivo.
Fujii T; Kitaura H; Kimura K; Hakami ZW; Takano-Yamamoto T
Bone; 2012 Oct; 51(4):771-80. PubMed ID: 22776139
[TBL] [Abstract][Full Text] [Related]
7. Docosahexaenoic Acid Inhibits Inflammation-Induced Osteoclast Formation and Bone Resorption
Kishikawa A; Kitaura H; Kimura K; Ogawa S; Qi J; Shen WR; Ohori F; Noguchi T; Marahleh A; Nara Y; Ichimura A; Mizoguchi I
Front Endocrinol (Lausanne); 2019; 10():157. PubMed ID: 30949128
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo.
Ishida M; Shen WR; Kimura K; Kishikawa A; Shima K; Ogawa S; Qi J; Ohori F; Noguchi T; Marahleh A; Kitaura H
Biomed Pharmacother; 2019 Jan; 109():242-253. PubMed ID: 30396082
[TBL] [Abstract][Full Text] [Related]
9. Quercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cells.
Guo C; Hou GQ; Li XD; Xia X; Liu DX; Huang DY; Du SX
Cell Physiol Biochem; 2012; 30(1):123-36. PubMed ID: 22759961
[TBL] [Abstract][Full Text] [Related]
10. [Effect of lipopolysaccharide on osteoclasts formation and bone resorption function and its mechanism].
Zeng L; Xu Y; Xing G
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2018 May; 32(5):568-574. PubMed ID: 29806344
[TBL] [Abstract][Full Text] [Related]
11. Azilsartan inhibits inflammation-triggered bone resorption and osteoclastogenesis
Fan Z; Kitaura H; Ren J; Ohori F; Noguchi T; Marahleh A; Ma J; Kanou K; Miura M; Narita K; Lin A; Mizoguchi I
Front Endocrinol (Lausanne); 2023; 14():1207502. PubMed ID: 37795376
[TBL] [Abstract][Full Text] [Related]
12. Aminothiazoles inhibit RANKL- and LPS-mediated osteoclastogenesis and PGE2 production in RAW 264.7 cells.
Kats A; Norgård M; Wondimu Z; Koro C; Concha Quezada H; Andersson G; Yucel-Lindberg T
J Cell Mol Med; 2016 Jun; 20(6):1128-38. PubMed ID: 26987561
[TBL] [Abstract][Full Text] [Related]
13. Expression of osteoclastogenic and anti-osteoclastogenic cytokines differs in mouse gingiva injected with lipopolysaccharide, peptidoglycan, or both.
Ozaki Y; Kishimoto T; Yamashita Y; Kaneko T; Higuchi K; Mae M; Oohira M; Mohammad AI; Yanagiguchi K; Yoshimura A
Arch Oral Biol; 2021 Feb; 122():104990. PubMed ID: 33259988
[TBL] [Abstract][Full Text] [Related]
14. Sciadopitysin suppresses RANKL-mediated osteoclastogenesis and prevents bone loss in LPS-treated mice.
Cao J; Lu Q; Liu N; Zhang YX; Wang J; Zhang M; Wang HB; Sun WC
Int Immunopharmacol; 2017 Aug; 49():109-117. PubMed ID: 28575726
[TBL] [Abstract][Full Text] [Related]
15. (D-Ala
Lin A; Kitaura H; Ohori F; Noguchi T; Marahleh A; Ma J; Ren J; Miura M; Fan Z; Narita K; Mizoguchi I
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473802
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of 1,25-dihydroxyvitamin D
Li ZF; Cao LH; Wang Y; Zhang Z; Fan MW; Xu QA
Arch Oral Biol; 2016 Dec; 72():146-156. PubMed ID: 27597534
[TBL] [Abstract][Full Text] [Related]
17. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
18. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
19. Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo.
Kimura K; Kitaura H; Fujii T; Hakami ZW; Takano-Yamamoto T
FEMS Immunol Med Microbiol; 2012 Mar; 64(2):219-27. PubMed ID: 22067001
[TBL] [Abstract][Full Text] [Related]
20. IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo.
Yoshimatsu M; Kitaura H; Fujimura Y; Eguchi T; Kohara H; Morita Y; Yoshida N
Bone; 2009 Nov; 45(5):1010-6. PubMed ID: 19651258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
